Novel Dry Eye Treatment Pathways: Understanding the MOA
With so many pharmaceutical treatment options, how do you decide which treatment to prescribe? From dry eye flares to chronic dry eye therapies, Dr. Doug Devries will provide his insights on how the mechanism of action (MOA) for our current and newest dry eye treatment options impacts his decision making and management.
As a global specialized company dedicated to ophthalmology, Santen brings a 130-year history of scientific knowledge and organizational capabilities to research, development, and commercialization of pharmaceuticals, surgical and medical devices, and OTC eye-care products. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan, and its products now reach patients in more than 60 countries. Santen provides products and services to contribute to the well-being of patients, their loved ones, and consequently to society. For more information, please visit Santen’s websites www.santenusa.com and www.santen.com (Japan headquarters).
